Spreadex Market Update

RFK Jr. Tanks Pharma Stocks, Nvidia Earnings Loom



Pharmaceutical stocks fell heavily across the US and Europe on Friday as President-elect Donald Trump lined up vaccine critic Robert Kennedy Junior to head up the Department of Health and Human Services. Attention now shifts to Trump’s potential Treasury Secretary picks, including Kevin Warsh and Marc Rowan. Markets are focussed on Nvidia’s upcoming results, with expectations of an 80% revenue surge in Q3 to $32.9 billion The dollar climbed versus yen overnight after BOJ Governor Kazuo Ueda provided no clear timeline for rate hikes.

Equities

The FTSE 100 edged down 0.1% on Friday, marking its fourth consecutive weekly decline, as shares in major pharmaceutical companies weighed on the index. AstraZeneca fell 3.1% and GSK slipped 3.9%, in line with broader losses among vaccine makers following US President-elect Donald Trump’s announcement of Robert F. Kennedy Jr. as his pick to lead the Department of Health and Human Services. Concerns over his stance on vaccines affected sentiment across the sector. Meanwhile, the midcap FTSE 250 index also dipped 0.2%.

Not all sectors struggled. Land Securities rose 4.3% after projecting annual earnings above market expectations, providing some relief to an otherwise subdued market. TT Electronics surged 40% after rejecting two takeover offers from Volex Plc, which itself fell 11% following the failed bids.

On Wall Street, US indices closed sharply lower on Friday. The S&P 500 dropped 1.32%, while the Nasdaq slid 2.24%—their largest one-day losses in two weeks—amid concerns about a slower pace of interest rate cuts and investor reactions to Trump’s cabinet picks. The Dow Jones Industrial Average lost 0.7%. Applied Materials saw its stock tumble 9.2% after forecasting first-quarter revenue below Wall Street expectations, dragging down the Philadelphia Semiconductor Index by 3.4%.

Vaccine makers Moderna and Pfizer also declined sharply, with shares falling 7.3% and 4.7% respectively, contributing to a 1.88% drop in the healthcare sector. Consumer staples stocks were similarly pressured by Trump’s nomination of Kennedy, with Monster Beverage down 7%, Lamb Weston off 6%, and Keurig Dr Pepper shedding 5%.

Forex & Commodities

The US dollar rose 0.35% against the yen to 154.72 after Bank of Japan Governor Kazuo Ueda hinted at future interest rate increases but gave no firm timeline. This followed warnings from Japan’s Finance Minister Katsunobu Kato about potential intervention to stabilise the yen, which had pulled the currency back slightly last week. Against a basket of currencies, the dollar held steady at 106.660, near Friday’s one-year high of 107.07, bolstered by a sharp rise in 10-year Treasury yields since October.

Gold prices climbed nearly 1% to $2,584.80 per ounce, rebounding from last week’s sharp sell-off. A pause in the dollar’s rally provided relief to bullion, which is sensitive to movements in the greenback.

Oil prices inched higher after escalations in the Russia-Ukraine conflict raised geopolitical concerns. Brent crude futures rose 0.3% to $71.22 per barrel, while US West Texas Intermediate crude added 0.1%, reaching $67.08. Over the weekend, Russia launched a major airstrike on Ukraine, intensifying tensions. However, forecasts of a global oil surplus and weak demand in China have capped gains.

DISCLAIMER


Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 64% of retail investors lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money. For professional clients, spread betting and CFD trading can also result in losses larger than your initial stake or deposit.

Spreadex Ltd is authorised and regulated by the Financial Conduct Authority, provides an execution only service and does not provide advice in any way. Nothing within this update should be deemed to constitute the provision of investment advice, recommendations, any other professional advice in any way, or a record of our trading prices. This update does not constitute or form part of an offer of, or solicitation for a transaction in any financial instrument, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefore. Any persons placing trades based on their interpretation of the comments or information within this update does so entirely at their own risk.

No representation, warranty, or undertaking, express or limited, is given as to the accuracy or completeness of the information or opinions contained within this update by Spreadex Ltd or any of its employees and no liability is accepted by such persons for the accuracy or completeness of any such information or opinions. As such, no reliance may be placed for any purpose on the information and opinions contained within this update.

The information contained within this update is the intellectual property of Spreadex Ltd and is protected by UK and International copyright laws. All rights reserved. Users may however freely download, distribute and reproduce extracts of the contents, subject always to accrediting Spreadex Ltd as the source and providing a hyperlink to www.spreadex.com.